Depression research published in 2025 (page 15)

Brief Mindfulness Meditation via Video Streaming Improves Depression, Anxiety, and Perceived Stress Among Schoolteachers: A Randomized Controlled Trial

Psychology in the Schools July 9, 2025 Kenjiro Tsubono, Sachiko Mitoku

Schoolteachers are considered as one of the most stressful professions worldwide. This study aimed to investigate the effect of brief mindfulness meditation practice via video streaming on schoolteachers' mental health. Public school teachers were recruited through paper flyers and relevant social media. Participants were randomly assigned to either the meditation or the control group. Blind...

DOI: 10.1002/pits.70040 Education

Naturalistic psychedelic use and changes in depressive symptoms.

Journal of Affective Disorders July 9, 2025 Otto Simonsson, Peter S. Hendricks, Caroline M. Swords et al. 8 citations

While growing evidence suggests that psychedelic-assisted therapy may have antidepressant effects in certain populations, little is known about the effects of psychedelic use on depressive symptoms in non-clinical, naturalistic settings. This observational cohort study included a large sample of US residents (18-50 years old) and longitudinally evaluated the relationships between naturalistic...

DOI: 10.1016/j.jad.2025.119857 Full text Depression Increased depressive symptoms Negative outcomes Adverse effects +5

In silico investigation of ketamine and methylphenidate drug-drug conjugate for MDD and ADHD treatment using MD simulations and MMGBSA

Scientific Reports July 8, 2025 Beenish Asrar, Nouman Ali, Imran Ali et al.

Major depressive disorder (MDD) and Attention-deficit hyperactivity disorder (ADHD) are pervasive psychiatric disorders characterized by impaired memory, sustained attention/motivation, and depression. FDA-approved Ketamine is an antidepressant drug but it affects cognitive abilities. Methylphenidate is the drug used for the treatment of ADHD. Chronic treatment overcomes attention and mental...

DOI: 10.1038/s41598-024-82302-0

Effect of online mindfulness intervention on anxiety, depression, and stress in patients with chronic diseases.

Explore July 8, 2025 Ying-Ju Chen, Chiu-Hsiang Lee, Chia-Jung Hsieh et al. 1 citation

Online mindfulness may be an effective non-pharmacological mental health intervention. To evaluate the effectiveness of an online mindfulness platform in ameliorating anxiety, depression, and stress in patients with chronic diseases. In this randomized controlled study, 97 patients were enrolled and randomly assigned to either the online intervention group (N = 47) or the control group (N =...

DOI: 10.1016/j.explore.2025.103214 Full text Anxiety Depression Adults Chronic disease +2

Antidepressant effects of esketamine are associated with functional connectivity in the hippocampal subregion: A resting state magnetic resonance study.

Neuroscience July 8, 2025 Xiang Liu, Yumeng Liu, Jun Tu et al. 2 citations

We aimed to investigate the relationship between changes in resting-state functional connectivity in a subregion of the hippocampus and the antidepressant effects of esketamine as well as to identify potential neuroimaging markers of the treatment outcomes. Twenty-nine patients with major depressive disorder (MDD) received six intravenous infusions of esketamine. All patients completed the...

DOI: 10.1016/j.neuroscience.2025.07.016 Full text Esketamine Major depressive disorder Mdd Functional connection +14

S-ketamine ameliorates post-stroke depression in mice via attenuation of neuroinflammation, synaptic restoration, and BDNF pathway activation.

Biochemical and Biophysical Research Communications July 8, 2025 Jiaxin Tian, Yanhong Xie, Sen Ye et al. 6 citations

The available therapeutic options for post-stroke depression patients are limited. Although SSRIs are the most commonly prescribed antidepressants, their slow onset of action and the higher risk of adverse effects or contraindications have led to an urgent need to develop fast-acting and highly specific antidepressants tailored to the needs of PSD patients. Therefore, ketamine has drawn...

DOI: 10.1016/j.bbrc.2025.151965 Full text S-ketamine Neuroinflammation Post-stroke depression psd Synaptic function +5

Mu Opioid Receptor Activation is Required for NMDA Receptor Antagonist Effects on Stress-induced Maladaptive Behavior.

Biological Psychiatry July 7, 2025 Cory B Langreck, Briana K Chen, Victor M Luna et al. 9 citations

Contradictory evidence has emerged regarding the role of the mu opioid receptor (MOR) in the antidepressant actions of (R,S)-ketamine. Here, we used the long-acting MOR-selective antagonist methocinnamox (MCAM) to determine the contribution of MOR to the actions of (R,S)-ketamine and the more selective N-methyl-D-aspartate receptor (NMDAR) antagonist fluoroethylnormemantine (FENM) against...

DOI: 10.1016/j.biopsych.2025.07.004 Full text Ketamine Fear Nmdar antagonists nmdar Similar compounds +10

An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression

July 7, 2025 Balázs Szigeti preprint

Background: Individuals with bipolar II disorder (BD-II) and depression face limited treatment options and are often excluded from psilocybin therapy trials due to theoretical concerns of precipitating mania or psychosis. Although psilocybin has demonstrated antidepressant effects when combined with psychotherapy, adverse event reporting is inconsistent, and restrictive eligibility criteria...

DOI: 10.31234/osf.io/97cqx_v1 Psychedelic-assisted therapy Psilocybin therapy Psilocybin treatment Mushroom therapy +15

Explore the effect of psilocybin on depression and anxiety

Arts, Culture and Language July 6, 2025 Yutong Song

Psilocybin, also known as “magic mushrooms,” is naturally found in psychedelic compound from different types of mushrooms. The utility of psilocybin for spiritual and therapeutic purposes has already go through several centuries. Scientific research on these compounds gained traction in the mid-20th century, the increasing interest in the possible therapeutic benefits of psilocybin has led to...

DOI: 10.61173/rcg8me57 Full text Psilocybin Anxiety Depression economics Clinical psychology +4

Esketamine disinhibits brain networks in depression: Evidence from oscillatory and aperiodic activity.

Progress in Neuro-Psychopharmacology and Biological Psychiatry July 5, 2025 Verina Guirguis, Sanvi Korsapathy, Francesca Pupillo et al. 6 citations

Nasal Esketamine is a rapid-acting intervention for depression, hypothesized to exert its effects through cortical disinhibition. However, the spatio-temporal dynamics of brain network activity and their relationship to the subjective drug experience following Esketamine administration remain elusive. This observational study aims to delineate brain network-level effects of Esketamine by...

DOI: 10.1016/j.pnpbp.2025.111438 Full text Major depressive disorder Aperiodic exponent Brain oscillations Esketamine treatment +9

Mindfulness-based interventions for cancer patients in standard treatment: A meta-analysis of effects on depression, anxiety, and quality of life.

Journal of Psychosomatic Research July 5, 2025 Ema Štánerová, Veronika Zelenayová, Jakub Rajčáni 8 citations

Mindfulness interventions are indicated to be effective in reducing psychological symptoms faced by patients with cancer. However, there is a lack of revised evidence on their effectiveness during the active treatment phase. To address this research gap, we conducted a meta-analysis of controlled clinical trials with adult patients written in English, published in PubMed, Web of Science,...

DOI: 10.1016/j.jpsychores.2025.112312 Full text Mindfulness Quality of life Cancer Interventions +9

Plasma esketamine and noresketamine levels and antidepressant response with oral esketamine treatment.

European Journal of Pharmacology July 5, 2025 Jolien K E Veraart, Sanne Y Smith-Apeldoorn, Jeanine Kamphuis et al. 2 citations

Oral esketamine has relatively low and variable bioavailability, which may complicate broader use as an antidepressant. This study aimed to investigate associations between different pharmacokinetic outcomes and change in depressive symptoms following oral esketamine administration in patients with treatment-resistant depression. Understanding such associations may inform dosing and...

DOI: 10.1016/j.ejphar.2025.177470 Full text Mdd Spravato Clinical depression Esketamine ketamine +5

Can self-compassion and mindfulness predict psychological wellbeing in individuals with endometriosis? Findings from an online survey.

BMC Women's Health July 4, 2025 Federica Facchin, Francesca Grosso, Emanuela Saita et al.

Background: Endometriosis presents diagnostic challenges and has profound impacts, encompassing physical and psychological symptoms, relationship difficulties, and disruptions in daily life. The emotional burden is pervasive, intensified by feelings of anxiety, depression, guilt, and shame. Despite extensive exploration of risk factors such as pelvic pain, knowledge about protective factors for...

DOI: 10.1186/s12905-025-03852-7 Full text Depression Mindfulness Humans Endometriosis +13

Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial.

JAMA Psychiatry July 2, 2025 Adam Janik, Xin Qiu, Rosanne Lane et al. 40 citations

Esketamine nasal spray, administered in conjunction with an oral antidepressant, is approved for treatment-resistant depression (TRD). However, the efficacy of esketamine nasal spray administered as monotherapy for patients with TRD has not yet been evaluated. To assess the efficacy and safety of esketamine monotherapy compared to placebo in reducing depressive symptoms in patients with TRD....

DOI: 10.1001/jamapsychiatry.2025.1317 Full text Esketamine nasal spray Treatment-resistant depression Depression treatment Antidepressant therapy +35

EMBRACE Study: Outcomes of a Randomized, Mindfulness-Based Intervention for Adults with Congenital Heart Disease.

Pediatric cardiology July 2, 2025 Vicki A Freedenberg, Rachel Steury, Robert Podolsky et al.

Adults with congenital heart disease (ACHD) have high rates of anxiety and depression. Strategies to manage the stress of having a chronic disease, improve coping skills and resilience can reduce these rates. To examine the effectiveness of an ACHD-specific, real-time virtual mindfulness-based behavioral intervention (MBBI) on mental health and resilience. A randomized wait-list control study...

DOI: 10.1007/s00246-025-03933-2 Full text Anxiety Depression Congenital heart disease Coping +6

Understanding the Experience of Ketamine-Assisted Therapy and the Importance of Context.

Journal of Psychoactive Drugs July 2, 2025 Grace Stockwell, Nicholas Hoeh, Francesca Fogarty et al. 2 citations

Ketamine-assisted therapy (KAT) is a novel modality that shows promise as a treatment for depression. The current study sought to add to the scarce research in the area and inform future applications of KAT for patients with treatment-resistant depression. The study used in-depth qualitative interviews (N = 12) to explore participants' perceptions of KAT, including working with therapists, the...

DOI: 10.1080/02791072.2025.2527299 Full text Ketamine-assisted therapy Depression treatment Therapeutic environment

The effectiveness of mindfulness-based cognitive therapy on metacognition, depression, and self-concept of children with anxiety disorders

Quarterly Journal of Child Mental Health July 1, 2025 Mozhgan Mazaheri, Nasrin Saeedi Farid, Narges Asgari Toorzani et al.

Background and Purpose: Anxiety disorders in children are among the most prevalent mental health issues, with widespread negative impacts on their emotional, cognitive

DOI: 10.61882/jcmh.12.2.1 Full text

A Pilot Randomized Controlled Trial Testing the Feasibility and Acceptability of Helping Ease Anxiety and Depression after Stroke (HEADS: UP): An Online Mindfulness-Based Intervention for Stroke Survivors

Mindfulness July 1, 2025 Maggie Lawrence, Bridget Davis, Naomi E. Clark et al.

Abstract Objectives The purpose of this study was to assess feasibility and acceptability of a stroke-specific mindfulness-based intervention called Helping Ease Anxiety and Depression after Stroke (HEADS: UP). Method This study was a mixed-methods pilot randomized controlled trial comparing HEADS: UP to treatment as usual (TAU). HEADS: UP is a 9-week mindfulness intervention for stroke...

DOI: 10.1007/s12671-025-02595-8

Acceptability, Practicality and Preliminary Indications of Efficacy of a Blended Individual Mindfulness Intervention for Patients with Persistent Depression

Mindfulness July 1, 2025 Jonathan Hamilton, Kate Brennan, Daniel Brown et al.

Abstract Objectives Mindfulness training has been shown to be helpful in the treatment of depression. However, standard mindfulness-based interventions (MBIs) are still not widely available and sustaining a mindfulness practice can be difficult for patients with current depression. Alternative delivery formats may serve to address these problems. This study tested the acceptability,...

DOI: 10.1007/s12671-025-02598-5

Symptom Reduction and Deprescribing in a Patient With Treatment-Resistant Depression Using Sublingual Ketamine Troches: A Case Report.

Cureus July 1, 2025 Elizabeth Francis

Treatment-resistant depression (TRD) remains a significant clinical challenge, often accompanied by polypharmacy and comorbid anxiety or trauma-related disorders. This report describes a 37-year-old male with longstanding major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and social anxiety disorder who demonstrated limited response to traditional pharmacologic strategies,...

DOI: 10.7759/cureus.87343 Full text Psychedelic-assisted therapy Complex-PTSD Ketamine infusion Low dose ketamine

Studies